Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy

The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.

Inclusion Criteria:

• hepatocellular carcinoma
• treated with transcatheter arterial chemoembolization (TACE)
• HBVDNA > 10^3copies/mL, including alanine aminotransferase (ALT) normal patient
• expected survive time > 1 year
• HBV marker positive (anyone of HbsAg, HbsAb, HbeAg, HbeAb and HbcAb)

Exclusion Criteria:

• antiviral therapy history
• alanine aminotransferase (ALT) >400 U/L
• serum total bilirubin > 50 μmol/L
• HBVDNA > 10^9copies/mL
• extrahepatic metastasis or main portal vein embolus
• apparent cardiac or pulmonary dysfunction
• liver function: Child B or Child C
• HCV infection